<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - MEDROXYPROGESTERONE ACETATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>MEDROXYPROGESTERONE ACETATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Dysfunctional uterine bleeding</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5&#8211;10 mg daily for 5&#8211;10 days, repeated for 2 cycles, begin treatment on day 16&#8211;21 of cycle.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Secondary amenorrhoea</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5&#8211;10 mg daily for 5&#8211;10 days, repeated for 3 cycles, begin treatment on day 16&#8211;21 of cycle.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Mild to moderate endometriosis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg 3 times a day for 90 consecutive days, begin treatment on day 1 of cycle.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Progestogenic opposition of oestrogen HRT</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg daily for the last 14 days of each 28-day oestrogen HRT cycle.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Endometrial cancer</span>,
                <span class="indication">Renal cell cancer</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200&#8211;600 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Breast cancer</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.4&#8211;1.5 g daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                150 mg, to be administered within the first 5 days of cycle or within first 5 days after parturition (delay until 6 weeks after parturition if breast-feeding).</li>
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                104 mg, to be administered within first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding), injected into anterior thigh or abdomen, dose only suitable if no hormonal contraceptive use in previous month.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Long-term contraception</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                150 mg every 12 weeks, to be administered within the first 5 days of cycle or within first 5 days after parturition (delay until 6 weeks after parturition if breast-feeding).</li>
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                104 mg every 13 weeks, to be administered within first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding), injected into anterior thigh or abdomen, dose only suitable if no hormonal contraceptive use in previous month.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception (when patient changing from other hormonal contraception)</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Avoid&#8212;genital malformations and cardiac defects reported.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">subcutaneous</ph> use</h3>
              <p>Not known to be harmful.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Avoid in hepatic impairment.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">subcutaneous</ph> use</h3>
              <p>Caution in severe liver disease and recurrent cholestatic jaundice.</p><p>Avoid in liver tumour.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <h3 class="specificity">When used for <ph outputclass="indication">Mild to moderate endometriosis</ph> or <ph outputclass="indication">Progestogenic opposition of oestrogen HRT</ph> or <ph outputclass="indication">Dysfunctional uterine bleeding</ph> or <ph outputclass="indication">Secondary amenorrhoea</ph></h3>
              <p>Use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>severe arterial disease</li>
            <li>undiagnosed vaginal bleeding</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Breast discomfort, changes in libido, depression, dizziness, headache, indigestion, loss of vision during treatment (discontinue treatment if papilloedema or retinal vascular lesions), menstrual irregularities, nausea, pruritus, vomiting, weight gain,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>rare:</strong> osteoporosis, osteoporotic fractures, osteoporosis, osteoporotic fractures,
              </p>
              <p>
                <strong>notKnown:</strong> disturbance of appetite, injection site-reactions, reduced bone mineral density, skin disorders, acne, adrenergic-like effects (when used for malignant disease), alopecia, anaphylactoid reactions, bloating, breast tenderness, cervical erosions (when used for malignant disease), confusion (when used for malignant disease), congestive heart failure (when used for malignant disease), constipation (when used for malignant disease), diarrhoea (when used for malignant disease), drowsiness, dry mouth (when used for malignant disease), euphoria (when used for malignant disease), fluid retention, galactorrhoea (when used for malignant disease), glucocorticoid effects may lead to a cushingoid syndrome (with high doses for malignant disease), hirsutism, hypercalcaemia (when used for malignant disease), hyperpyrexia (when used for malignant disease), hypertension (when used for malignant disease), insomnia, jaundice, loss of concentration (when used for malignant disease), nervousness (when used for malignant disease), palpitation (when used for malignant disease), premenstrual-like syndrome, raised platelet count (when used for malignant disease), raised white blood cell count (when used for malignant disease), rash, retinal thrombosis (when used for malignant disease), skin reactions, tachycardia (when used for malignant disease), urticaria, vision disorders (when used for malignant disease), disturbance of appetite, injection site-reactions, reduced bone mineral density, skin disorders,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">subcutaneous</ph> use</h3>
                <p class="title">Cervical cancer</p>
              <p>Use of injectable progestogen-only contraceptives may be associated with a small increased risk of cervical cancer, similar to that seen with combined oral contraceptives. The risk of cervical cancer with other progestogen-only contraceptives is not yet known.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">subcutaneous</ph> use</h3>
              <p>Reduction in bone mineral density occurs in the first 2&#8211;3 years of use then stabilises.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">subcutaneous</ph> use</h3>
              <p>Full counselling backed by <i>patient information leaflet</i> required before administration&#8212;likelihood of menstrual disturbance and the potential for a delay in return to full fertility. Delayed return of fertility and irregular cycles may occur after discontinuation of treatment but there is no evidence of permanent infertility.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Possible risk of breast cancer
          </li>
        </ul>
        <ul>
          <li>
              <strong>With intramuscular use:</strong>
            history during pregnancy in disturbances of lipid metabolism
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            history during pregnancy of deterioration of otosclerosis
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            history during pregnancy of pruritus
          </li>
          <li>
              <strong>With oral use:</strong>
            asthma
          </li>
          <li>
              <strong>With oral use:</strong>
            cardiac dysfunction
          </li>
          <li>
              <strong>With oral use:</strong>
            conditions that may worsen with fluid retention
          </li>
          <li>
              <strong>With oral use:</strong>
            diabetes (progestogens can decrease glucose tolerance&#8212;monitor patient closely)
          </li>
          <li>
              <strong>With oral use:</strong>
            epilepsy
          </li>
          <li>
              <strong>With oral use:</strong>
            history of depression
          </li>
          <li>
              <strong>With oral use:</strong>
            hypertension
          </li>
          <li>
              <strong>With oral use:</strong>
            migraine
          </li>
          <li>
              <strong>With oral use:</strong>
            susceptibility to thromboembolism (particular caution with high dose)
          </li>
          <li>
              <strong>With subcutaneous use:</strong>
            history during pregnancy in disturbances of lipid metabolism
          </li>
          <li>
              <strong>With subcutaneous use:</strong>
            history during pregnancy of deterioration of otosclerosis
          </li>
          <li>
              <strong>With subcutaneous use:</strong>
            history during pregnancy of pruritus
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use</h3>
              <p>If interval between dose is greater than 12 weeks and 5 days (in long-term contraception), rule out pregnancy before next injection and advise patient to use additional contraceptive measures (e.g. barrier) for 14 days after the injection.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">subcutaneous</ph> use</h3>
              <p>If interval between dose is greater than 13 weeks and 7 days (in long-term contraception), rule out pregnancy before next injection.</p>
            </section>
      </section>












      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of MEDROXYPROGESTERONE ACETATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP75466"><a href="../medicinalForm/PHP75466.html" data-target="#PHP75466" data-action="load">Tablet</a></div>
            <div id="PHP75484"><a href="../medicinalForm/PHP75484.html" data-target="#PHP75484" data-action="load">Suspension for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
